feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Canadians urged: Get vaccines

trending

IRS stimulus direct deposit rumors

trending

Nvidia: 'one team' culture

trending

Retirement income policies review

trending

Virus linked to lupus cases

trending

Telegram's Cocoon AI accelerates

trending

Bitcoin price drops below $100,000

trending

FIFA U-17 World Cup thrills

trending

Walmart CEO Doug McMillon retires

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Pioneering Scientists Crack the Code of Autoimmune Diseases

Pioneering Scientists Crack the Code of Autoimmune Diseases

13 Nov

•

Summary

  • Researchers use advanced technology to study rogue immune cells
  • New treatments aim to fix dysfunctional immune pathways, not just suppress symptoms
  • Researchers make breakthroughs in understanding diseases like lupus, myositis, and Type 1 diabetes
Pioneering Scientists Crack the Code of Autoimmune Diseases

As of November 2025, scientists are making significant strides in decoding the causes of autoimmune diseases and developing more targeted treatments. Researchers are using sophisticated technology, including laser-powered machinery and fluorescent dyes, to closely examine rogue immune cells that attack the body's own tissues.

At the National Institutes of Health (NIH) and Johns Hopkins University, teams are unraveling the complex mechanisms behind conditions like Type 1 diabetes, lupus, and myositis. They have gained new insights into how the immune system can turn against the body, with rogue T cells and antibodies causing damage. Importantly, these researchers are not just aiming to tamp down symptoms, but to fix the underlying dysfunctional immune pathways.

Early-phase clinical trials are now underway for treatments that address the root causes of autoimmune diseases, which affect tens of millions globally. Scientists are also developing next-generation therapies, including nanoparticle-based approaches and drugs that selectively target harmful immune cells. These breakthroughs offer hope for more effective and personalized care for patients struggling with these debilitating conditions.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Researchers at Johns Hopkins University are developing nanoparticle-based treatments to dial down pancreas-killing cells and ramp up "peacemaker" cells in Type 1 diabetes.
Dr. Mariana Kaplan's team at the NIH is hunting the underlying causes of lupus and other autoimmune diseases, exploring what makes the immune system run amok and why these conditions often strike women.
Dr. Iago Pinal-Fernandez's research at the NIH has shown that rogue antibodies in myositis, a group of muscle-weakening autoimmune diseases, can sneak inside muscle cells and disrupt their normal functions, helping explain the varying symptoms.

Read more news on

Healthside-arrow

You may also like

Childhood Hypertension Epidemic Sweeps the Globe

1 day ago • 7 reads

article image

Gout Drug Colchicine Linked to Reduced Heart Attack and Stroke Risk

1 day ago • 4 reads

article image

Delgocitinib Cream Approved for NHS Use, Offering Relief to 62,000 Eczema Patients

1 day ago • 6 reads

article image

Global TB Cases Reach Record High in 2024

12 Nov • 49 reads

article image

Hearing Loss Epidemic Grips UK, Millions Struggle to Seek Help

1 day ago • 7 reads

article image